佩拉曼奈尔每日4毫克剂量的认知和行为影响
Kimford J Meador1, Jordan Seliger1, Scheherazade Le1
1Department of Neurology & Neurological Sciences, Stanford University Palo Alto CA United States.
Epilepsy & behavior : E&B
|January 17, 2025
概括
每日4毫克的佩拉曼奈尔在健康志愿者身上显示出最小的神经心理效应. 这种抗发作药物在定位和维护阶段耐受性很好.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 抗发作药物 (ASM) 可能会导致剂量依赖的神经心理效应,影响治疗的耐受性和有效性.
- 之前对帕拉曼奈尔 (PER) 的评估没有使用客观措施广泛评估其每日4毫克剂量的认知效应.
研究的目的:
- 在健康的志愿者中研究四毫克每日剂量的perampanel (PER) 的神经心理效应.
- 评估PER治疗的定位和维持阶段的认知和行为变化.
主要方法:
- 一项针对健康志愿者的随机双盲研究,在6周的时间内,每天评估PER 4毫克 (定位2周,维持4周).
- 使用由认知和行为测试得出的复合Z分数来评估神经心理效应,并对特定领域和原始分数进行二次分析.
主要成果:
- 在基线,定位和维护阶段的整体复合Z分数中没有发现显著差异.
- 个体认知和行为领域Z-score也显示,定位率之间没有显著差异.
- 对原始分数的探索性分析表明,在19项措施中,只有两个措施具有边际意义.
结论:
- 每天4毫克的佩拉曼奈尔在健康志愿者中耐受良好.
- 该研究发现,与这种剂量PER相关的显著神经心理效应很少.
相关概念视频
Antiepileptic Drugs: Potassium Channel Activators
149
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
149
Sedatives and Hypnotics Drugs: Miscellaneous Agents
157
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
157
Anxiolytic Drugs: Benzodiazepines and Buspirone
573
Benzodiazepines are a class of anxiolytic drugs known for their rapid efficacy and high therapeutic-to-lethal dose ratio, but with a potential risk of drug dependence. These drugs are lipophilic, allowing for rapid absorption after oral administration, eventually reaching the central nervous system (CNS). Once in the CNS, benzodiazepines bind to the allosteric site of the GABAA receptor. This binding enhances the inhibitory effects of the neurotransmitter GABA. By doing so, they prevent...
573
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
107
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
107
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
103
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
103
Parkinson's Disease: Treatment
235
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
235


